---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000087"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:51:44.487615+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics Q1 net loss $43.5M; cash $157M; ivonescimab shows 34% intracranial response in NSCLC brain mets

## Summary
- GAAP net loss $43.5M ($0.06/sh) vs $542.3M ($1.43/sh) prior year; non-GAAP net loss $34.0M ($0.05/sh).
- Cash and investments $157M at March 31; operating cash outflow $30.1M; guidance cash runway through Q1 2025.
- R&D expenses $30.9M GAAP, up from $9.9M; non-GAAP R&D $28.5M as trial enrollment expands.
- Ivonescimab Phase II data: 34% intracranial response rate; median intracranial PFS 19.3 months in NSCLC brain metastases; mPFS 11.1 months in first-line squamous NSCLC.
- HARMONi (EGFR-mutant NSCLC) enrollment completion expected H2 2024; HARMONi-3 (first-line squamous) first patient treated Q4 2023.

## SEC filing metadata
- accession: 0001599298-24-000087
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/0001599298-24-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/smmt-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000087
- JSON: https://secwatch.observer/filing/0001599298-24-000087.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000087.txt

## Key facts
- Earnings Releases
  Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 1, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/0001599298-24-000087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.